Plain-English translation of NCT04486833 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Carcinoma, Non-Small Cell Lung research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a combination of two medications for people with advanced lung cancer that has stopped responding to , a drug you may have already tried. The new treatment combines (an experimental gene therapy) with (a targeted lung cancer drug). The study wants to find the right dose and see whether this combination works better than standard chemotherapy.
Many patients with a specific type of lung cancer benefit from at first, but eventually their cancer starts growing again. Researchers believe that this medication, when combined with the existing drug, might help control the cancer longer or more effectively than chemotherapy alone.
You likely qualify if…
You likely don't qualify if…
If you are in the experimental group, you will receive intravenous infusions of the new medication once every 3 weeks and take an oral tablet of daily at home. If you are in the control group, you will receive standard . You will continue treatment until your cancer progresses or side effects become unacceptable. You will have regular visits for blood tests, imaging scans, and check-ins with your care team to monitor how you are doing.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
United States